Market Closed -
Nasdaq
04:00:00 2024-05-17 pm EDT
|
5-day change
|
1st Jan Change
|
16.17
USD
|
+0.87%
|
|
+1.06%
|
+10.75%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,044
|
1,583
|
1,271
|
1,413
|
-
|
-
|
Enterprise Value (EV)
1 |
759.2
|
1,241
|
1,040
|
1,217
|
1,201
|
1,195
|
P/E ratio
|
-3.65
x
|
-9.92
x
|
-6.16
x
|
-5.75
x
|
-7.56
x
|
-16.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
94.8
x
|
17.2
x
|
6.14
x
|
EV / Revenue
|
-
|
-
|
-
|
81.6
x
|
14.6
x
|
5.19
x
|
EV / EBITDA
|
-10.5
x
|
-8.45
x
|
-5.05
x
|
-4.5
x
|
-4.97
x
|
-123
x
|
EV / FCF
|
-15.6
x
|
-11.3
x
|
-7.07
x
|
-7.28
x
|
-10.5
x
|
-42.4
x
|
FCF Yield
|
-6.39%
|
-8.86%
|
-14.1%
|
-13.7%
|
-9.56%
|
-2.36%
|
Price to Book
|
3.71
x
|
-
|
3.36
x
|
4.96
x
|
5.48
x
|
6.86
x
|
Nbr of stocks (in thousands)
|
61,929
|
73,550
|
87,043
|
87,390
|
-
|
-
|
Reference price
2 |
16.85
|
21.52
|
14.60
|
16.17
|
16.17
|
16.17
|
Announcement Date
|
3/7/22
|
3/6/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
14.91
|
82.05
|
230
|
EBITDA
1 |
-
|
-72.54
|
-146.8
|
-206
|
-270.5
|
-241.7
|
-9.7
|
EBIT
1 |
-
|
-72.74
|
-146.9
|
-206.1
|
-260.3
|
-213.8
|
-81.08
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,745.9%
|
-260.57%
|
-35.25%
|
Earnings before Tax (EBT)
1 |
-
|
-72.75
|
-142.2
|
-188.9
|
-245.4
|
-190.8
|
-87.91
|
Net income
1 |
-40.51
|
-170.6
|
-142.2
|
-188.9
|
-247
|
-201.8
|
-97.51
|
Net margin
|
-
|
-
|
-
|
-
|
-1,656.94%
|
-245.9%
|
-42.4%
|
EPS
2 |
-17.03
|
-4.620
|
-2.170
|
-2.370
|
-2.814
|
-2.138
|
-0.9784
|
Free Cash Flow
1 |
-
|
-48.54
|
-109.9
|
-147.1
|
-167.1
|
-114.8
|
-28.18
|
FCF margin
|
-
|
-
|
-
|
-
|
-1,120.65%
|
-139.88%
|
-12.25%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/4/21
|
3/7/22
|
3/6/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.9081
|
4.461
|
9.792
|
19.71
|
26.59
|
EBITDA
|
-21.92
|
-27.74
|
-36.71
|
-39.66
|
-42.73
|
-
|
-
|
-51.43
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.98
|
-27.75
|
-36.72
|
-39.7
|
-42.74
|
-45.86
|
-49.25
|
-51.44
|
-59.52
|
-66.77
|
-68.08
|
-63.03
|
-59.63
|
-49.58
|
-44.56
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-7,497.4%
|
-1,412.91%
|
-609.02%
|
-251.58%
|
-167.59%
|
Earnings before Tax (EBT)
1 |
-21.94
|
-27.75
|
-36.53
|
-37.8
|
-40.11
|
-42.39
|
-45.86
|
-46.15
|
-54.51
|
-62.41
|
-64.91
|
-60.99
|
-57.28
|
-47.92
|
-42.6
|
Net income
1 |
-21.94
|
-27.75
|
-36.53
|
-37.8
|
-40.11
|
-42.39
|
-45.86
|
-46.15
|
-54.51
|
-62.41
|
-64.11
|
-60.86
|
-57.21
|
-47.92
|
-42.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-7,059.4%
|
-1,364.2%
|
-584.26%
|
-243.13%
|
-160.2%
|
EPS
2 |
-0.3540
|
-0.4800
|
-0.6000
|
-0.5300
|
-0.5600
|
-0.5900
|
-0.6100
|
-0.5400
|
-0.6400
|
-0.7200
|
-0.7350
|
-0.6950
|
-0.6388
|
-0.5250
|
-0.4650
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/7/22
|
5/12/22
|
8/4/22
|
11/7/22
|
3/6/23
|
5/1/23
|
8/7/23
|
11/6/23
|
2/26/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
284
|
342
|
231
|
196
|
212
|
218
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-48.5
|
-110
|
-147
|
-167
|
-115
|
-28.2
|
ROE (net income / shareholders' equity)
|
-
|
-150%
|
-46.4%
|
-55.7%
|
-102%
|
-63.2%
|
-27.5%
|
ROA (Net income/ Total Assets)
|
-
|
-102%
|
-44.5%
|
-52.1%
|
-73.5%
|
-55.5%
|
-22.9%
|
Assets
1 |
-
|
167.7
|
319.4
|
362.5
|
336.2
|
363.4
|
424.9
|
Book Value Per Share
2 |
-
|
4.540
|
-
|
4.340
|
3.260
|
2.950
|
2.360
|
Cash Flow per Share
2 |
-
|
-
|
-1.680
|
-1.840
|
-0.7700
|
-2.470
|
-
|
Capex
1 |
-
|
-
|
0.03
|
0.22
|
4.2
|
4.34
|
4.39
|
Capex / Sales
|
-
|
-
|
-
|
-
|
28.19%
|
5.29%
|
1.91%
|
Announcement Date
|
5/4/21
|
3/7/22
|
3/6/23
|
2/26/24
|
-
|
-
|
-
|
Last Close Price
16.17
USD Average target price
35.78
USD Spread / Average Target +121.26% Consensus |
1st Jan change
|
Capi.
|
---|
| +10.75% | 1.4B | | +33.63% | 50.85B | | -0.09% | 42.82B | | +49.62% | 42.03B | | -4.96% | 29.55B | | +11.18% | 26.11B | | -21.95% | 19.13B | | +8.61% | 13.05B | | +28.31% | 12.16B | | +24.73% | 12.08B |
Other Biotechnology & Medical Research
|